Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Friedlaender

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Swiss Medical Weekly|April 3, 2023
Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort studyNoémie Lang, Aurélie Ayme, Chang Ming, et al.
Microorganisms|October 23, 2021
SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical CohortFlorian Laubscher, Samuel Cordey, Alex Friedlaender, et al.
Cancers|November 27, 2021
Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical TrialsPamela Trillo Aliaga, Dario Trapani, José Luis Sandoval, et al.
Cancer Immunology, Immunotherapy : CII|April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortSabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.
Familial Cancer|April 29, 2023
Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literatureKetty Hu-Heimgartner, Noémie Lang, Aurélie Ayme, et al.
Breast Cancer Research and Treatment|January 13, 2019
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsAlex Friedlaender, Aurélie Vuilleumier, Valeria Viassolo, et al.
Scientific Reports|April 29, 2020
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Translational Lung Cancer Research|October 17, 2022
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective studyKai-Qi Jin, Xiao-Gang Liu, Yan-Hua Guo, et al.
Scientific Reports|November 3, 2020
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Swiss Medical Weekly|April 3, 2023
Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort studyNoémie Lang, Aurélie Ayme, Chang Ming, et al.
Microorganisms|October 23, 2021
SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical CohortFlorian Laubscher, Samuel Cordey, Alex Friedlaender, et al.
Cancers|November 27, 2021
Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical TrialsPamela Trillo Aliaga, Dario Trapani, José Luis Sandoval, et al.
Cancer Immunology, Immunotherapy : CII|April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortSabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.
Familial Cancer|April 29, 2023
Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literatureKetty Hu-Heimgartner, Noémie Lang, Aurélie Ayme, et al.
Breast Cancer Research and Treatment|January 13, 2019
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsAlex Friedlaender, Aurélie Vuilleumier, Valeria Viassolo, et al.
Scientific Reports|April 29, 2020
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Translational Lung Cancer Research|October 17, 2022
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective studyKai-Qi Jin, Xiao-Gang Liu, Yan-Hua Guo, et al.
Scientific Reports|November 3, 2020
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Pageof 11